Vesigen
Delivering Therapies to Previously Undruggable Targets
Vesigen’s patented technology uses ARRDC1 Mediated Microvesicles—or ARMMs—to deliver a range of payloads to previously undruggable targets. Our ARMMed particles can deliver RNAs, proteins, and gene editing complexes directly into the cell cytoplasm, creating new therapeutic opportunities across multiple disease areas.